A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy- N,N -dimethyltryptamine) in patients with treatment-resistant depression
Journal of Psychopharmacology February 27, 2026 Claire T. Roberts, Mathieu Seynaeve, Anna O. Ermakova et al.
Results confirmed the safety profile of BPL-003 in a TRD population. A rapid and sustained reduction in MADRS score was observed over 12 weeks, suggesting BPL-003 could be beneficial in TRD, warranting investigation in larger controlled trials.
DOI: 10.1177/02698811261420087 (opens in new tab)
Treatment-resistant depression
Major depressive disorder
Depression economics
Nasal administration
+5